MOB-015 data to be presented at the 73rd Annual Meeting of the American Academy of Dermatology
STOCKHOLM, March 13, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that Professor Jan Faergemann, Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden and Principal Investigator of the phase-II clinical trial on the Company’s product candidate for onychomycosis MOB-015, will present at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) on March 22, 2015 in San Francisco, CA.
The annual AAD meeting features world-renowned leaders presenting the latest research in the diagnosis and medical, surgical and cosmetic treatment of skin, hair and nail conditions.
Professor Faergemann will present a poster on the principal results of the recently completed phase-II clinical trial with MOB-015, Moberg Pharma’s proprietary topical terbinafine formulation for treatment of onychomycosis (nail fungus). The presentation will be held on Sunday, 3/22/2015 from 10:30 to 10:35 AM at Center E-Poster Presentation, Center 2 in the Infection - Fungal section. The poster will be available on the Company's website at www.mobergpharma.com in the morning after the presentation.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail: peter.wolpert@mobergpharma.se
Kjell Rensfeldt, VP R&D, Telephone: +46 (0)70 – 712 4532, Email: kjell.rensfeldt@mobergpharma.se
About this information
The information was submitted for publication at 08:45 am (CET) on March 13, 2015.
About MOB-015 and Onychomycosis
Onychomycosis and related problems has been the main focus of Moberg Pharma since its inception in 2006. The company markets Kerasal Nail®, the leading product in the U.S. over-the-counter (OTC) fungal nail category, through its OTC sales team and through distributors in approximately 30 countries. MOB-015 is a proprietary topical formulation of terbinafine developed internally by Moberg Pharma and builds on the company’s experience from the OTC market.
Terbinafine is currently the world’s most widely used oral prescription treatment for onychomycosis and was a blockbuster before patent expiration. Topical administration of terbinafine eliminates concerns of oral treatment, including drug interactions and risk for liver injury, but has previously not been successful due to insufficient delivery of the active substance through the nail. Moberg Pharma’s preclinical and clinical data confirm that MOB-015 delivers effective levels of terbinafine through the nail and into the nail bed.
Onychomycosis is a common nail infection caused predominantly by dermatophyte fungi, which typically occurs under the toenails, although fingernails may also be affected. Approximately 10% of the general population suffers from onychomycosis. In the U.S., MOB-015 targets the attractive prescription market, which, after recent launches of two new topical treatments, is expected to exceed $2 billion in the U.S. alone. The untapped potential is significant since the majority of patients are untreated.
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®as well as Phase II pipeline assets. Kerasal Nail®(Emtrix®and Nalox™in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.
Tags: